Home
Storia in 1 fonti
Broker’s Call: Alkem Laboratories (Add)
Semaglutide (GLP-1) launch has seen good progress (for its injectable), as the company was able to capture about 11% market share, which should further improve in subsequent months
Raccontata da
thehindubusinessline.com
Timeline cronologica
- ·
Alkem Labs stock jumps after Q4 revenue growth and upbeat FY27 outlook
Shares of Alkem Laboratories surged over 6 per cent in early trade on Friday after the company reported strong revenue growth for the March quarter and issued a positive outlook…
- ·
Broker’s Call: Alkem Laboratories (Add)
Semaglutide (GLP-1) launch has seen good progress (for its injectable), as the company was able to capture about 11% market share, which should further improve in subsequent months